fluidigm (nasdaq:fldm) develops, manufactures and markets microfluidic systems for growth markets in the life sciences and in applied markets. fluidigm’s systems consist of instruments, software, integrated fluidic circuits (ifcs), high-performance assays for gene expression and genotyping, and primers for sample preparation for next-generation sequencing. fluidigm technology enables customers to perform thousands of sophisticated biochemical measurements in parallel on samples smaller than the content of a single cell, with nanoliter volumes of reagents, in half the area of a credit card. the company’s integrated customer solutions are designed to significantly simplify experimental workflows, increase throughput and reduce costs while delivering excellent data quality. based in south san francisco, fluidigm offers an exciting and collegial working environment with excellent compensation and benefits, including equity.
![Standard BioTools logo](/files/LOGO/1162194-LAB.png)
Company profile
Ticker
LAB
Exchange
Website
CEO
Stephen Linthwaite
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
FLUIDIGM CORP
SEC CIK
Corporate docs
Subsidiaries
SB Sciences Inc. • Standard BioTools (Shanghai) Instrument Technology Company Limited • Standard BioTools K.K. • Standard BioTools Europe B.V. • Standard BioTools Singapore Pte. Ltd. • SomaLogic, Inc. • Standard BioTools France SARL • Standard BioTools GmbH • Standard BioTools Italy S.r.l. • Standard BioTools UK Limited ...
IRS number
770513190
LAB stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
1 Jul 24
EFFECT
Notice of effectiveness
28 Jun 24
S-3
Shelf registration
18 Jun 24
DEFA14A
Additional proxy soliciting materials
3 Jun 24
8-K
Other Events
3 Jun 24
SD
Conflict minerals disclosure
29 May 24
ARS
2023 FY
Annual report to shareholders
21 May 24
DEFC14A
Proxy in contested solicitation
21 May 24
PRER14A
Preliminary revised proxy
20 May 24
PREC14A
Preliminary proxy with contested solicitation
10 May 24
Transcripts
LAB
Earnings call transcript
2024 Q1
8 May 24
LAB
Earnings call transcript
2023 Q4
28 Feb 24
LAB
Earnings call transcript
2023 Q3
7 Nov 23
LAB
Earnings call transcript
2023 Q2
8 Aug 23
LAB
Earnings call transcript
2023 Q1
9 May 23
LAB
Earnings call transcript
2022 Q4
14 Feb 23
LAB
Earnings call transcript
2022 Q3
9 Nov 22
LAB
Earnings call transcript
2022 Q2
9 Aug 22
LAB
Earnings call transcript
2022 Q1
8 May 22
LAB
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
4
Eli Casdin
23 Jul 24
4
Frank Witney
2 Jul 24
4
Troy Cox
2 Jul 24
4
Eli Casdin
2 Jul 24
4
FENEL M ELOI
2 Jul 24
4
Thomas D. Carey
2 Jul 24
4
KATHY L HIBBS
2 Jul 24
3
Initial statement of insider ownership
26 Jun 24
144
Notice of proposed sale of securities
24 Jun 24
144
Notice of proposed sale of securities
24 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 288.34 mm | 288.34 mm | 288.34 mm | 288.34 mm | 288.34 mm | 288.34 mm |
Cash burn (monthly) | (no burn) | (no burn) | 20.06 mm | 10.02 mm | 20.83 mm | 8.11 mm |
Cash used (since last report) | n/a | n/a | 77.57 mm | 38.73 mm | 80.53 mm | 31.35 mm |
Cash remaining | n/a | n/a | 210.77 mm | 249.61 mm | 207.81 mm | 257.00 mm |
Runway (months of cash) | n/a | n/a | 10.5 | 24.9 | 10.0 | 31.7 |
Institutional ownership, Q1 2024
70.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 139 |
Opened positions | 133 |
Closed positions | 0 |
Increased positions | 2 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 668.56 bn |
Total shares | 261.51 mm |
Total puts | 400.00 |
Total calls | 356.02 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Casdin Capital | 61.91 mm | $167.77 bn |
Viking Global Investors | 58.65 mm | $158.94 bn |
Millennium Management | 14.37 mm | $38.95 bn |
ARK Investment Management | 13.04 mm | $35.35 bn |
Vanguard | 13.03 mm | $35.32 bn |
CMTDF Sumitomo Mitsui Trust | 8.85 mm | $23.99 bn |
Nikko Asset Management Americas | 8.85 mm | $23.99 bn |
MS Morgan Stanley | 7.62 mm | $20.64 bn |
Indaba Capital Management | 7.36 mm | $19.95 bn |
Caligan Partners | 7.04 mm | $13.17 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Jul 24 | Casdin Eli | Common Stock | Grant | Acquire A | No | No | 0 | 1,588 | 0.00 | 2,752,332 |
28 Jun 24 | Kathy L Hibbs | Common Stock | Grant | Acquire A | No | No | 0 | 43,128 | 0.00 | 43,128 |
28 Jun 24 | Kathy L Hibbs | Stock Option Common Stock | Grant | Acquire A | No | No | 1.77 | 72,213 | 127.82 k | 72,213 |
28 Jun 24 | Casdin Eli | Common Stock | Grant | Acquire A | No | No | 0 | 43,128 | 0.00 | 2,750,744 |
28 Jun 24 | Casdin Eli | Stock Option Common Stock | Grant | Acquire A | No | No | 1.77 | 72,213 | 127.82 k | 72,213 |
28 Jun 24 | Fenel M Eloi | Common Stock | Grant | Acquire A | No | No | 0 | 43,128 | 0.00 | 141,591 |
28 Jun 24 | Fenel M Eloi | Stock Option Common Stock | Grant | Acquire A | No | No | 1.77 | 72,213 | 127.82 k | 72,213 |
28 Jun 24 | Carey Thomas D. | Common Stock | Grant | Acquire A | No | No | 0 | 43,128 | 0.00 | 43,128 |
28 Jun 24 | Carey Thomas D. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.77 | 108,319 | 191.72 k | 108,319 |
News
Standard Biotools Filed For Offering Of Up To 105.1M Common Shares By The Selling Securityholders
20 Jun 24
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
23 May 24
$3.5M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
20 May 24
Standard BioTools Reaffirms FY24 Revenue Guidance Of $200M-$205M
8 May 24
Standard BioTools Q1 2024 GAAP EPS $(0.27) Misses $(0.12) Estimate, Sales $45.540M Miss $46.006M Estimate
8 May 24
Press releases
Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024
17 Jul 24
Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers
28 May 24
Standard BioTools to Participate in Upcoming Investor Conferences
22 May 24
Standard BioTools Reports First Quarter 2024 Financial Results
8 May 24